Outlook Therapeutics’ (OTLK) Neutral Rating Reiterated at Chardan Capital

Chardan Capital restated their neutral rating on shares of Outlook Therapeutics (NASDAQ:OTLK) in a research report sent to investors on Monday, MarketBeat.com reports.

Other analysts have also recently issued research reports about the company. Ascendiant Capital Markets cut their target price on Outlook Therapeutics from $35.00 to $33.00 and set a “buy” rating for the company in a research report on Tuesday, September 3rd. BTIG Research lowered their target price on shares of Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating on the stock in a report on Friday, November 29th. Finally, HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Outlook Therapeutics in a report on Friday, November 29th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $42.34.

Outlook Therapeutics Price Performance

Shares of OTLK stock opened at $1.66 on Monday. Outlook Therapeutics has a one year low of $0.87 and a one year high of $12.85. The company’s fifty day moving average price is $5.06 and its 200-day moving average price is $6.59. The company has a market capitalization of $39.27 million, a price-to-earnings ratio of -0.16 and a beta of 0.46.

Insider Activity at Outlook Therapeutics

In other news, CFO Lawrence A. Kenyon bought 5,000 shares of the stock in a transaction dated Thursday, September 26th. The stock was purchased at an average price of $5.69 per share, for a total transaction of $28,450.00. Following the acquisition, the chief financial officer now owns 5,946 shares of the company’s stock, valued at $33,832.74. The trade was a 528.54 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 3.40% of the stock is owned by insiders.

Institutional Trading of Outlook Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of OTLK. Great Point Partners LLC increased its stake in Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company’s stock worth $12,557,000 after buying an additional 221,510 shares during the period. Rosalind Advisors Inc. increased its position in shares of Outlook Therapeutics by 44.3% during the second quarter. Rosalind Advisors Inc. now owns 450,000 shares of the company’s stock worth $3,321,000 after acquiring an additional 138,225 shares during the period. Geode Capital Management LLC raised its stake in shares of Outlook Therapeutics by 49.2% during the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after acquiring an additional 112,812 shares in the last quarter. LVW Advisors LLC bought a new stake in shares of Outlook Therapeutics during the second quarter valued at approximately $352,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in Outlook Therapeutics in the second quarter worth approximately $303,000. Hedge funds and other institutional investors own 11.20% of the company’s stock.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.